僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I （IL-1RI） signaling receptor instead of IL-1 counter-regulatory decoy receptor （IL-1 receptor type II）